Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

firstwordpharma.com
firstwordpharma.com > story > 7983565

AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial

1+ day, 7+ hour ago   (12+ words) firstwordpharma.com...

firstwordpharma.com
firstwordpharma.com > story > 7973027

Friday Five??? Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal???and more

3+ day, 12+ hour ago   (19+ words) Friday Five – Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal…and more firstwordpharma.com...

FirstWord Pharma
firstwordpharma.com > story > 7965266

Physician Views Preview: How are prescribing patterns changing in COPD?

5+ day, 7+ hour ago   (12+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7960382

Moonwalk unveils gene silencing approach to obesity, $70M in fresh funds

6+ day, 50+ min ago   (13+ words) FirstWord Pharma...

firstwordpharma.com
firstwordpharma.com > story > 7958314

Vital Signs: Who's enjoying the fruits of pharma's labor?

6+ day, 20+ hour ago   (10+ words) firstwordpharma.com...

FirstWord Pharma
firstwordpharma.com > story > 7957772

Physician Views Preview: Can AstraZeneca's Etcamah carve out a new treatment paradigm in breast cancer?

1+ week, 21+ min ago   (17+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7957440

Novo's hopes for ziltivekimab dwindle as two heart failure studies stopped early

1+ week, 3+ hour ago   (14+ words) FirstWord Pharma...

firstwordpharma.com
firstwordpharma.com > story > 7953711

Vital Signs: Novartis, Sanofi place their bets on SC longevity for key products

1+ week, 1+ day ago   (14+ words) firstwordpharma.com...

FirstWord PHARMA
firstwordpharma.com > story > 7944820

GSK pays up to $1.3B for HUTCHMED's experimental KRAS-EGFR conjugate

1+ week, 4+ day ago   (12+ words) FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7942137

Physician Views Preview: Is Ionis' Dawnzera making its mark on HAE prophylaxis?

1+ week, 4+ day ago   (14+ words) FirstWord Pharma...